Marlen Haderlein1, Claudia Scherl2, Sabine Semrau3, Sebastian Lettmaier3, Markus Hecht3, Ramona Erber4, Heinrich Iro2, Rainer Fietkau3, Abbas Agaimy4. 1. Department of Radiation Oncology, University Hospital of Erlangen, Universitätsstraße 27, 91054, Erlangen, Germany. marlen.haderlein@uk-erlangen.de. 2. Department of Otorhinolaryngology, University Hospital of Erlangen, Erlangen, Germany. 3. Department of Radiation Oncology, University Hospital of Erlangen, Universitätsstraße 27, 91054, Erlangen, Germany. 4. Institute of Pathology, University Hospital of Erlangen, Erlangen, Germany.
Abstract
AIM: Retrospective Investigation of the prognostic relevance of clinicopathologic parameters in patients with salivary duct carcinoma (SDC). METHODS: An experienced pathologist reviewed 67 patients with de novo SDC or SDC ex pleomorphic adenoma. Paraffin-embedded tumor samples were examined by immunohistochemistry for expression of HER2/neu, androgen (AR), progesterone (PR), estrogen (ER), epidermal growth factor (EGFR) and programmed death ligand 1 (PD-L1-R) receptor. In 45 patients who had cM0 and follow-up data available, survival rates were calculated (Kaplan-Meier method) and prognostic variables were analyzed (univariate analysis: log-rank test; multivariate analysis: Cox-regression analysis). RESULTS: Overexpression of HER2/neu, AR, ER, PR, EGFR, PD-L1-R was found in 25.4%, 84%, 0%, 0%, 17.9%, 16.4% of patients. Overall (OS), disease-free (DFS), distant-metastases-free survival (DMFS) and locoregional control (LRC) were 92.3/72.4/56.9%, 78.2/58.1/58.1%, 85.4/65.2/65.2% and 89.7/81.9/81.9% after 1/3/5 years (medial follow-up 26 months). In univariate analysis a positive resection margin (p = 0.008) and no postoperative radiotherapy (p = 0.001) predict an increased locoregional recurrence rate. In multivariate analysis only postoperative radiotherapy is statistically significant (p = 0.004). Presence of lymph node metastases, a lymph node density >4 and HER2/neu overexpression predict decreased DFS and DMFS. In multivariate HER2/neu overexpression was the only significant predictor for reduced DFS (p = 0.04) and DMFS (p = 0.02). CONCLUSION: Postoperative radiotherapy is the only significant predictor for LRC. HER2/neu receptor expression is an independent prognostic factor for decreased DFS and DMFS in patients with SDC. In addition to radio(chemo)therapy, intensified first-line treatment regimens should also be evaluated in the future.
AIM: Retrospective Investigation of the prognostic relevance of clinicopathologic parameters in patients with salivary duct carcinoma (SDC). METHODS: An experienced pathologist reviewed 67 patients with de novo SDC or SDC ex pleomorphic adenoma. Paraffin-embedded tumor samples were examined by immunohistochemistry for expression of HER2/neu, androgen (AR), progesterone (PR), estrogen (ER), epidermal growth factor (EGFR) and programmed death ligand 1 (PD-L1-R) receptor. In 45 patients who had cM0 and follow-up data available, survival rates were calculated (Kaplan-Meier method) and prognostic variables were analyzed (univariate analysis: log-rank test; multivariate analysis: Cox-regression analysis). RESULTS: Overexpression of HER2/neu, AR, ER, PR, EGFR, PD-L1-R was found in 25.4%, 84%, 0%, 0%, 17.9%, 16.4% of patients. Overall (OS), disease-free (DFS), distant-metastases-free survival (DMFS) and locoregional control (LRC) were 92.3/72.4/56.9%, 78.2/58.1/58.1%, 85.4/65.2/65.2% and 89.7/81.9/81.9% after 1/3/5 years (medial follow-up 26 months). In univariate analysis a positive resection margin (p = 0.008) and no postoperative radiotherapy (p = 0.001) predict an increased locoregional recurrence rate. In multivariate analysis only postoperative radiotherapy is statistically significant (p = 0.004). Presence of lymph node metastases, a lymph node density >4 and HER2/neu overexpression predict decreased DFS and DMFS. In multivariate HER2/neu overexpression was the only significant predictor for reduced DFS (p = 0.04) and DMFS (p = 0.02). CONCLUSION: Postoperative radiotherapy is the only significant predictor for LRC. HER2/neu receptor expression is an independent prognostic factor for decreased DFS and DMFS in patients with SDC. In addition to radio(chemo)therapy, intensified first-line treatment regimens should also be evaluated in the future.
Authors: Jie Xu; Heather H Sun; Christopher D M Fletcher; Jason L Hornick; Elizabeth A Morgan; Gordon J Freeman; F Stephen Hodi; Geraldine S Pinkus; Scott J Rodig Journal: Am J Surg Pathol Date: 2016-04 Impact factor: 6.394
Authors: Yoshitsugu Mitani; Pulivarthi H Rao; Sankar N Maity; Yu-Chen Lee; Renata Ferrarotto; Julian C Post; Lisa Licitra; Scott M Lippman; Merrill S Kies; Randal S Weber; Carlos Caulin; Sue-Hwa Lin; Adel K El-Naggar Journal: Clin Cancer Res Date: 2014-10-14 Impact factor: 12.531
Authors: Peter P Luk; Jared D Weston; Bing Yu; Christina I Selinger; Rafael Ekmejian; Timothy J Eviston; Trina Lum; Kan Gao; Michael Boyer; Sandra A O'Toole; Jonathan R Clark; Ruta Gupta Journal: Head Neck Date: 2015-12-24 Impact factor: 3.147
Authors: Michael Jaehne; Kerstin Roeser; Thorsten Jaekel; Jan David Schepers; Natalie Albert; Thomas Löning Journal: Cancer Date: 2005-06-15 Impact factor: 6.860
Authors: Meredith L Johnston; Shao Hui Huang; John N Waldron; Eshetu G Atenafu; Kelvin Chan; Bernard J Cummings; Ralph W Gilbert; David Goldstein; Patrick J Gullane; Jonathan C Irish; Bayardo Perez-Ordonez; Ilan Weinreb; Andrew Bayley; John Cho; Laura A Dawson; Andrew Hope; Jolie Ringash; Ian J Witterick; Brian O'Sullivan; John Kim Journal: Head Neck Date: 2015-07-15 Impact factor: 3.147
Authors: Silvana Di Palma; Roderick H W Simpson; Caterina Marchiò; Alena Skálová; Marco Ungari; Ann Sandison; Stephen Whitaker; Suzanne Parry; Jorge S Reis-Filho Journal: Histopathology Date: 2012-10 Impact factor: 5.087
Authors: Ming-Hui Mao; Jian-Guo Zhang; Lei Zheng; Hong Gao; Jie Zhang; Shu-ming Liu; Ming-wei Huang; Yan Shi Journal: Strahlenther Onkol Date: 2014-09-09 Impact factor: 3.621
Authors: Sebastian Adeberg; Paul Windisch; Felix Ehret; Melissa Baur; Sati Akbaba; Thomas Held; Denise Bernhardt; Matthias F Haefner; Juergen Krauss; Steffen Kargus; Christian Freudlsperger; Peter Plinkert; Christa Flechtenmacher; Klaus Herfarth; Juergen Debus; Stefan Rieken Journal: Front Oncol Date: 2019-12-20 Impact factor: 6.244
Authors: Sarina K Mueller; Marlen Haderlein; Sebastian Lettmaier; Abbas Agaimy; Florian Haller; Markus Hecht; Rainer Fietkau; Heinrich Iro; Konstantinos Mantsopoulos Journal: J Clin Med Date: 2022-01-29 Impact factor: 4.241